keyword
MENU ▼
Read by QxMD icon Read
search

Liposomal amphotericin b formulation

keyword
https://www.readbyqxmd.com/read/28490252/visceral-leishamiosis-in-immunocompromised-host-an-update-and-literature-review
#1
Pasquale Pagliano, Silvano Esposito
Visceral leishmaniasis (VL) is a chronic infectious disease endemic in tropical and sub-tropical areas including the Mediterranean basin, caused by a group of protozoan parasites of the genus Leishmania and transmitted by phlebotomine sandflies. Immunocompromised patients, in particular HIV positive, are considered at risk of VL. They report atypical signs and poor response to treatment due to impairment of T-helper and regulatory cells activity. Laboratory diagnosis is based on microscopy on bone marrow or spleen aspirates...
May 10, 2017: Journal of Chemotherapy
https://www.readbyqxmd.com/read/28480760/tissue-pharmacokinetics-and-pharmacodynamics-of-ambisome%C3%A2-l-ambis-in-uninfected-and-infected-animals-and-their-effects-on-dosing-regimens
#2
J P Adler-Moore, R T Proffitt, J A Olson, G M Jensen
By selecting a unique combination of lipids and amphotericin B, the liposome composition for AmBisome (L-AmBis) has been optimized resulting in a formulation that is minimally toxic, targets to fungal cell walls, and distributes into and remains for days to weeks in various host tissues at drug levels above the MIC for many fungi. Procedures have been standardized to ensure that large scale production of the drug retains the drug's low toxicity profile, favorable pharmacokinetics and antifungal efficacy. Tissue accumulation and clearance with single or multiple intravenous administration is similar in uninfected and infected animal species, with tissue accumulation being dose-dependent and the liver and spleen retaining the most drug...
May 7, 2017: Journal of Liposome Research
https://www.readbyqxmd.com/read/28420334/mucormycosis-in-renal-transplant-recipients-review-of-174-reported-cases
#3
Yan Song, Jianjun Qiao, Gaffi Giovanni, Guangjun Liu, Hao Yang, Jianyong Wu, Jianghua Chen
BACKGROUND: Mucormycosis is a highly lethal fungal infection especially in immunocompromised individuals. METHODS: In order to review the epidemiology, diagnosis, and treatment of mucormycosis in renal transplant recipients we searched publications of mucormycosis cases in renal transplant recipients in PUBMED database up to December 2015. RESULTS: A total of 174 cases in renal transplant recipients were included in this review. Most of the cases (76%) were male...
April 18, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28339539/unique-aggregation-of-conjugated-amphotericin-b-and-its-interaction-with-lipid-membranes
#4
Sarah Kagan, Diana E Ickowicz, Abraham J Domb, Arie Dagan, Itzhack Polacheck
The purpose of this paper was to investigate the aggregation of amphotericin B (AMB) and AMB-arabinogalactan conjugate (AMB-AGC), and the interactions of these drugs with free and membrane-embedded sterols. Aggregation of AMB and AMB-AGC was studied by circular dichroic (CD) and UV absorbance spectroscopic techniques. The effect of liposomes on the spectra was utilized to investigate the interactions of aggregates with membrane-embedded sterols. Interaction with free sterols was studied by measuring sterols' effect on AMB/AMB-AGC susceptibility test...
June 1, 2017: Medical Mycology: Official Publication of the International Society for Human and Animal Mycology
https://www.readbyqxmd.com/read/28216467/nmr-and-esr-study-of-amphotericin-b-interactions-with-various-binary-phosphatidylcholine-phosphatidylglycerol-membranes
#5
J C Debouzy, L Mehenni, D Crouzier, M Lahiani-Skiba, G Nugue, M Skiba
Several biologically relevant phospholipids are considered as potential excipients for IV administration liposome's formulation of AMB (Biopharmaceututics Classification System Class IV). On the basis of in vivo bioavaibility studies, DMPC and DMPG were ranked as the first potent encapsulation enhancers for this model drug, especially if one expects to target DMPG rich systems as pulmonary surfactant. Subsequently, dispersions (multilayers) of DMPC, DMPG or in binary systems with various molar ratios were prepared with or without AMB (molar ratios AMB/lipid) and further investigated using the (1)H-,(31)P-NMR methods...
February 16, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28216150/novel-biodegradable-poly-gamma-glutamic-acid-amphotericin-b-complexes-show-promise-as-improved-amphotericin-b-formulations
#6
T Dinh, Q Zia, S Zubair, P Stapleton, R Singh, M Owais, S Somavarapu
Commercially available amphotericin B (AmB) formulations are limited by cytotoxicities, lower efficacies, shelf-life related issues or high production costs. AmB complexes based on poly(gamma-glutamic acid) (PGGA) have been prepared and evaluated for their efficacies against AmB-deoxycholate (Fungizone®) and liposomal AmB (AmBisome®). Physical characterizations showed that AmB/PGGA complexes are nanoscopic (20-40 nm) with a negative zeta potential (-51.0 mV), water-soluble, stable in solution (up to 4 weeks, at 4 °C and 25 °C), and have a theoretical drug loading (up to 76...
February 16, 2017: Nanomedicine: Nanotechnology, Biology, and Medicine
https://www.readbyqxmd.com/read/28191796/the-cost-of-treating-mucormycosis-with-isavuconazole-compared-with-standard-therapy-in-the-uk
#7
Emma Bagshaw, Daniel Kuessner, Jan Posthumus, Cesar Escrig, Michael Blackney, Sebastian Marcel Heimann, Oliver Andreas Cornely
AIM: Mucormycosis is a fungal infection associated with high mortality. Until recently, the only licensed treatments were amphotericin B (AMB) formulations. Isavuconazole (ISAV) is a new mucormycosis treatment. A UK-based economic model explored treatment costs with ISAV versus liposomal AMB followed by posaconazole. MATERIALS & METHODS: As a matched case-control analysis showed similar efficacy for ISAV and AMB, a cost-minimization approach was taken. Direct costs - drug acquisition, monitoring and administration, and hospitalization costs - were estimated from the National Health Service perspective...
February 13, 2017: Future Microbiology
https://www.readbyqxmd.com/read/28097002/ambisome-induced-avascular-necrosis-of-the-alae-of-the-nose-of-a-very-young-girl-suffering-from-kala-azar-a-case-report
#8
Shomik Maruf, Proggananda Nath, Fatima Aktar, Ariful Basher
Although liposomal amphotericin B (AmBisome) is considered as the first-line treatment for New Kala-azar, there is not enough evidence on the dosage formulation in children and its effect on them. Being considered as the safest drug for treatment of Kala-azar, this case of AmBisome-induced avascular necrosis now gives rise to the question; whether it is actually safe enough and if a dosage modification is needed in case of children. This so far, to the best of our knowledge, is the first instance of such severe adverse event due to AmBisome administration...
December 2016: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/28011960/visceral-leishmaniasis-in-immunocompromised-diagnostic-and-therapeutic-approach-and-evaluation-of-the-recently-released-idsa-guidelines
#9
Pasquale Pagliano, Tiziana Ascione, Giusy Di Flumeri, Giovanni Boccia, Francesco De Caro
Visceral Leishmaniasis (VL) is a chronic infectious disease endemic in tropical and sub-tropical areas including the Mediterranean basin, caused by a group of protozoan parasites of the genus Leishmania and transmitted by phlebotomine sandflies. Typically, VL is classified as a zoonotic infection when Leishmania infantum is the causative agent and as an anthroponotic one when L. donovani is the causative agent. Immunocompromised patients, in particular HIV positive, are considered at risk of VL. They may present atypical signs and poor response to the treatment due to a compromission of T-helper and regulatory cells activity...
December 1, 2016: Le Infezioni in Medicina
https://www.readbyqxmd.com/read/27878878/efficacy-and-safety-of-amphotericin-b-lipid-based-formulations-a-systematic-review-and-meta-analysis
#10
REVIEW
Laiza M Steimbach, Fernanda S Tonin, Suzane Virtuoso, Helena H L Borba, Andréia C C Sanches, Astrid Wiens, Fernando Fernandez-Llimós, Roberto Pontarolo
Invasive fungal infections, an important cause of mortality, are primarily treated using amphotericin B, which is available in different formulations, both conventional and lipid-based (liposomal, lipid complex, colloidal dispersion and Intralipid(®) infusion). The aim of our study was to determine the efficacy and safety of conventional amphotericin B vs its lipid-based formulations. A systematic review followed by pairwise meta-analysis was performed, including randomised controlled trials (RCTs) that evaluated the use of lipid-based amphotericin B in patients with any degree of immunosuppression and susceptibility to invasive fungal infection...
March 2017: Mycoses
https://www.readbyqxmd.com/read/27855062/safety-tolerability-and-pharmacokinetics-of-liposomal-amphotericin-b-in-immunocompromised-pediatric-patients
#11
Nita L Seibel, Aziza T Shad, Ihor Bekersky, Andreas H Groll, Corina Gonzalez, Lauren V Wood, Paul Jarosinski, Donald Buell, William W Hope, Thomas J Walsh
The safety, tolerability, and pharmacokinetics of the liposomal formulation of amphotericin B (L-AMB) were evaluated in 40 immunocompromised children and adolescents. The protocol was an open-label, sequential-dose-escalation, multidose pharmacokinetic study with 10 to 13 patients in each of the four dosage cohorts. Each cohort received daily dosages of 2.5, 5.0, 7.5, or 10 mg of amphotericin B in the form of L-AMB per kg of body weight. Neutropenic patients between the ages of 1 and 17 years were enrolled to receive empirical antifungal therapy or treatment of documented invasive fungal infections...
February 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27747684/confusion-between-two-amphotericin-b-formulations-leading-to-a-paediatric-rehospitalisation
#12
Mapi Fleury, Caroline Fonzo-Christe, Charline Normand, Pascal Bonnabry
A heavily immunosuppressed, 43-kg, 9-year-old patient was recovering from a bone marrow transplant. Primary prophylaxis against invasive fungal infections was liposomal amphotericin B (AmBisome(®), 2.3 mg/kg [100 mg] two times per week). Once home, following a first amphotericin B infusion, he presented with strong diarrhoea and vomiting; this was repeated after the second infusion. The clinical situation worsened rapidly and the patient was rehospitalised. On admission, he presented with acute renal failure...
December 2016: Drug Safety—Case Reports
https://www.readbyqxmd.com/read/27605844/treatment-of-visceral-leishmaniasis-anomalous-pricing-and-distribution-of-ambisome-and-emergence-of-an-indigenous-liposomal-amphotericin-b-fungisome
#13
Pradyot Bhattacharya, Nahid Ali
Visceral leishmaniasis (VL) is one of the severest forms of parasite borne diseases worldwide with a mortality rate second only to malaria. Treatment of VL patients with currently available chemotherapeutic agents poses problems of large scale failure, toxicity, prolonged hospitalization time, high treatment cost and drug resistance. However, most of these problems can be overcome by the use of liposomal formulations of Amphotericin B (L-AmB). Of the two L-AmBs currently available in Indian market, AmBisome is imported and FUNGISOME is indigenous...
September 2016: Journal of Parasitic Diseases: Official Organ of the Indian Society for Parasitology
https://www.readbyqxmd.com/read/27540288/fungal-diseases-could-nanostructured-drug-delivery-systems-be-a-novel-paradigm-for-therapy
#14
REVIEW
Aline Raquel Voltan, Guillermo Quindós, Kaila P Medina Alarcón, Ana Marisa Fusco-Almeida, Maria José Soares Mendes-Giannini, Marlus Chorilli
Invasive mycoses are a major problem for immunocompromised individuals and patients in intensive care units. Morbidity and mortality rates of these infections are high because of late diagnosis and delayed treatment. Moreover, the number of available antifungal agents is low, and there are problems with toxicity and resistance. Alternatives for treating invasive fungal infections are necessary. Nanostructured systems could be excellent carriers for antifungal drugs, reducing toxicity and targeting their action...
2016: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/27401407/bioinspired-calcium-phosphate-nanoparticles-featuring-as-efficient-carrier-and-prompter-for-macrophage-intervention-in-experimental-leishmaniasis
#15
Mohini Chaurasia, Pankaj K Singh, Anil K Jaiswal, Animesh Kumar, Vivek K Pawar, Anuradha Dube, Sarvesh K Paliwal, Manish K Chourasia
PURPOSE: To develop a biocompatible and bioresorbable calcium phosphate (CaP) nanoparticles (NPs) bearing Amphotericin B (AmB) with an aim to provide macrophage specific targeting in visceral leishmaniasis (VL). MATERIALS & METHODS: CaP-AmB-NPs were architectured through emulsion precipitation method. The developed formulation was extensively characterized for various parameters including in-vitro and in-vivo antileishmanial activity. Moreover, plasma pharmacokinetics, tissue biodistribution and toxicity profile were also assessed...
November 2016: Pharmaceutical Research
https://www.readbyqxmd.com/read/27328721/ambisome-relationship-between-the-pharmacokinetic-characteristics-acquired-by-liposomal-formulation-and-safety-efficacy
#16
Koji Takemoto, Katsunori Kanazawa
Amphotericin B (AMPH-B) is a polyene antifungal agent with a superior and broad fungicidal spectrum, but its administration at a dose sufficient for treatment is difficult because of dose- and duration-dependent nephrotoxicity. To solve this dilemma, a liposomal formation of AMPH-B that achieved reduction of adverse effects while maintaining the efficacy, AmBisome® (L-AMB), was developed. In L-AMB, AMPH-B molecules are stabilized by phospholipids and cholesterol in the liposomal lipid bilayer, reducing the cytotoxicity for animal cells compared with that of the free-form AMPH-B...
June 21, 2016: Journal of Liposome Research
https://www.readbyqxmd.com/read/27222025/surface-modified-liposomal-formulation-of-amphotericin-b-in-vitro-evaluation-of-potential-against-visceral-leishmaniasis
#17
Shilpa N Patere, Pankaj O Pathak, Anil Kumar Shukla, Rajesh Kumar Singh, Vikash Kumar Dubey, Miten J Mehta, Anand G Patil, Vikram Gota, Mangal S Nagarsenker
Surface modification of liposomes with targeting ligands is known to improve the efficacy with reduced untoward effects in treating infective diseases like visceral leishmaniasis (VL). In the present study, modified ligand (ML), designed by modifying polysaccharide with a long chain lipid was incorporated in liposomes with the objective to target amphotericin B (Amp B) to reticuloendothelial system and macrophages. Conventional liposomes (CL) and surface modified liposomes (SML) were characterized for size, shape, and entrapment efficiency (E...
May 24, 2016: AAPS PharmSciTech
https://www.readbyqxmd.com/read/26818726/liposomal-amphotericin-b-ambisome-%C3%A2-a-review-of-the-pharmacokinetics-pharmacodynamics-clinical-experience-and-future-directions
#18
REVIEW
Neil R H Stone, Tihana Bicanic, Rahuman Salim, William Hope
Liposomal amphotericin B (AmBisome(®); LAmB) is a unique lipid formulation of amphotericin B. LAmB is a standard of care for a wide range of medically important opportunistic fungal pathogens. LAmB has a significantly improved toxicity profile compared with conventional amphotericin B deoxycholate (DAmB). Despite nearly 20 years of clinical use, the pharmacokinetics and pharmacodynamics of this agent, which differ considerably from DAmB, remain relatively poorly understood and underutilized in the clinical setting...
March 2016: Drugs
https://www.readbyqxmd.com/read/26768369/comparison-between-liposomal-formulations-of-amphotericin-b
#19
REVIEW
Jill P Adler-Moore, Jean-Pierre Gangneux, Peter G Pappas
Given the clinical success of commercial amphotericin B lipid products, investigators have begun making generic formulations of liposomal amphotericin B. Generic medicines are an attractive approach to help decrease the cost and accessibility to healthcare, provided that appropriate studies are performed to ensure bioequivalence with the parent product. This is of particular concern for liposomal drugs such as amphotericin B where liposomes are used as a carrier system to reduce the toxicity of the active agent...
March 2016: Medical Mycology: Official Publication of the International Society for Human and Animal Mycology
https://www.readbyqxmd.com/read/26709977/topical-amphotericin-b-in-ultradeformable-liposomes-formulation-skin-penetration-study-antifungal-and-antileishmanial-activity-in-vitro
#20
Ana Paula Perez, Maria Julia Altube, Priscila Schilrreff, Gustavo Apezteguia, Fabiana Santana Celes, Susana Zacchino, Camila Indiani de Oliveira, Eder Lilia Romero, Maria Jose Morilla
Aiming to improve the topical delivery of AmB to treat cutaneous fungal infections and leishmaniasis, ultradeformable liposomes containing amphotericin B (AmB-UDL) were prepared, and structural and functional characterized. The effect of different edge activators, phospholipid and AmB concentration, and phospholipid to edge activator ratio on liposomal deformability, as well as on AmB liposomal content, was tested. Liposomes having Tween 80 as edge activator resulted of maximal deformability and AmB/phospholipid ratio...
March 1, 2016: Colloids and Surfaces. B, Biointerfaces
keyword
keyword
101730
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"